MicroRNA-155 is a critical regulator of type 2 innate lymphoid cells and IL-33 signaling in experimental models of allergic airway inflammation

    loading  Checking for direct PDF access through Ovid



Allergic airway inflammation is triggered by allergen exposure through several steps including release of IL-33, which promotes cytokine (IL-5, IL-13) production by type 2 innate lymphoid cells (ILC2s). MicroRNA (miR)-155 has recently been described to regulate adaptive responses in allergic inflammation. However, the role of miR-155 in the regulation of ILC2s remains unexplored.


We sought to elucidate the contribution of miR-155 in ILC2 expansion using experimental murine models of allergic airway inflammation.


To determine the role of miR-155 in the regulation of ILC2s in allergic airway inflammation, miR-155 deficient (miR-155−/−) and wild-type (WT) mice were subjected to acute or chronic allergen-induced inflammation or treated with recombinant IL-33.


miR-155 was 10-fold upregulated in WT-derived ILC2s in response to IL-33. Furthermore, miR-155−/− mice demonstrated impaired lung IL-33 levels in response to allergen challenge and the number of ILC2s was significantly reduced in allergen-challenged miR-155−/− mice compared with WT mice. Exogenous IL-33 treatment revealed that miR-155 is needed for IL-33–induced ILC2 expansion and eosinophilic airway inflammation. Indeed, ILC2s from IL-33–challenged miR-155−/− lungs exhibited impaired proliferation, GATA-3 expression, and IL-13 production as compared with IL-33–challenged WT ILC2s.


Our findings for the first time demonstrate that ILC2s and IL-33 signaling are regulated by miR-155 in allergic airway inflammation.

Related Topics

    loading  Loading Related Articles